Tokyo (JCN) - Daiichi Sankyo Co., Ltd. has announced that its subsidiary Daiichi Pharmaceutical Co., Ltd. has signed an agreement to acquire 100% of the shares of Seoul-based Daiichi Pharmaceutical Korea Co., Ltd. ('KDP'), a joint venture with Jeil Pharmaceutical Co., Ltd. The acquisition will take effect on October 13, when KDP becomes a wholly
owned subsidiary of Daiichi Pharmaceutical. With this acquisition, the Daiichi Sankyo Group plans to actively expand
its business operations throughout Asia.
Copyright(C) 2006 Japan Corporate News Network. www.japancorp.net All rights reserved.
